Pfizer has a long-standing commitment to tackling antimicrobial resistance (AMR), as well as a willingness to collaborate with external stakeholders. Initiatives currently focus on an extensive range of programmes that go beyond the sale of our medicines, including; public awareness and educational programmes, education of healthcare professionals, responsible commercial and manufacturing activities and investment in surveillance programmes.
 

Pfizer is proud to have been recognized as the joint industry leader in the Access to Medicine Foundation’s 2021 AMR Benchmark Report, with the report highlighting our industry-leading policies to improve appropriate access to our medicines and curb the threat of AMR. We performed strongly in R&D, Responsible Manufacturing and Appropriate Access, were ranked leaders in Stewardship, and were commended for being the first pharmaceutical company to publicly share raw surveillance data from our antimicrobial surveillance website platform, the Antimicrobial Testing Leadership and Surveillance (ATLAS) database.¹